JP2011501959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501959A5 JP2011501959A5 JP2010532056A JP2010532056A JP2011501959A5 JP 2011501959 A5 JP2011501959 A5 JP 2011501959A5 JP 2010532056 A JP2010532056 A JP 2010532056A JP 2010532056 A JP2010532056 A JP 2010532056A JP 2011501959 A5 JP2011501959 A5 JP 2011501959A5
- Authority
- JP
- Japan
- Prior art keywords
- albumin
- fusion protein
- seq
- fragment
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010088751 Albumins Proteins 0.000 claims 105
- 102000009027 Albumins Human genes 0.000 claims 105
- 108020001507 fusion proteins Proteins 0.000 claims 47
- 102000037865 fusion proteins Human genes 0.000 claims 47
- 150000001413 amino acids Chemical group 0.000 claims 34
- 239000012634 fragment Substances 0.000 claims 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 26
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims 14
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims 14
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 208000035475 disorder Diseases 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 229960003920 cocaine Drugs 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 241000972773 Aulopiformes Species 0.000 claims 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 101000693916 Gallus gallus Albumin Proteins 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 101000930455 Ovis aries Albumin Proteins 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 208000008784 apnea Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000001784 detoxification Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims 2
- 235000019515 salmon Nutrition 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 210000005253 yeast cell Anatomy 0.000 claims 2
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003162 Arterial injury Diseases 0.000 claims 1
- 102000021944 Butyrylcholinesterase Human genes 0.000 claims 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010016803 Fluid overload Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 206010070606 Post stroke depression Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038540 Renal tubular necrosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010047139 Vasoconstriction Diseases 0.000 claims 1
- 208000033774 Ventricular Remodeling Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000025033 vasoconstriction Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/932,823 US20080194481A1 (en) | 2001-12-21 | 2007-10-31 | Albumin Fusion Proteins |
| PCT/US2008/012306 WO2009058322A1 (en) | 2007-10-31 | 2008-10-30 | Albumin fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013233069A Division JP5856131B2 (ja) | 2007-10-31 | 2013-11-11 | アルブミン融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011501959A JP2011501959A (ja) | 2011-01-20 |
| JP2011501959A5 true JP2011501959A5 (enExample) | 2011-12-15 |
Family
ID=40591364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532056A Pending JP2011501959A (ja) | 2007-10-31 | 2008-10-30 | アルブミン融合タンパク質 |
| JP2013233069A Active JP5856131B2 (ja) | 2007-10-31 | 2013-11-11 | アルブミン融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013233069A Active JP5856131B2 (ja) | 2007-10-31 | 2013-11-11 | アルブミン融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20080194481A1 (enExample) |
| EP (1) | EP2211888A4 (enExample) |
| JP (2) | JP2011501959A (enExample) |
| AU (1) | AU2008319332B2 (enExample) |
| CA (1) | CA2703943A1 (enExample) |
| IL (1) | IL204839A0 (enExample) |
| WO (1) | WO2009058322A1 (enExample) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| EP1463752A4 (en) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| WO2004096113A2 (en) * | 2003-04-28 | 2004-11-11 | Medical Instill Technologies, Inc. | Container with valve assembly for filling and dispensing substances, and apparatus and method for filling |
| PL2348114T3 (pl) | 2004-04-21 | 2019-08-30 | Alexion Pharmaceuticals, Inc. | Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość |
| US9222728B2 (en) | 2006-04-24 | 2015-12-29 | Medinstill Development Llc | Penetrable and resealable lyophilization device |
| AU2007258609B2 (en) | 2006-06-07 | 2013-01-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AR072524A1 (es) * | 2008-07-18 | 2010-09-01 | Novozymes As | Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos |
| US8232248B2 (en) * | 2008-07-18 | 2012-07-31 | Novozymes Adenium Biotech A/S | Treatment of rheumatoid arthritis with mammal beta defensins |
| CN102247591A (zh) * | 2008-07-18 | 2011-11-23 | 诺维信阿德宁生物技术公司 | 使用哺乳动物β防御素的炎性肠病的治疗 |
| CN102741275B (zh) | 2009-08-24 | 2016-08-03 | 阿穆尼克斯运营公司 | 凝血因子ix组合物及其制备和使用方法 |
| CN102711795A (zh) * | 2009-12-08 | 2012-10-03 | 泰华制药工业有限公司 | 用于治疗可卡因滥用的BChE白蛋白融合体 |
| JP2013519392A (ja) | 2010-02-16 | 2013-05-30 | メディミューン，エルエルシー | Ｈｓａ関連組成物および使用方法 |
| EP2658979B1 (en) | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| CA2826683A1 (en) * | 2011-02-15 | 2012-08-23 | Medimmune, Llc | Hsa-related compositions and methods of use |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| EP2678002A2 (en) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
| WO2012118042A1 (ja) * | 2011-02-28 | 2012-09-07 | 独立行政法人国立循環器病研究センター | 悪性腫瘍転移抑制用医薬 |
| CA2838833A1 (en) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Pro-coagulant compounds and methods of use thereof |
| SG10201601621PA (en) | 2011-06-28 | 2016-04-28 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| US9217021B2 (en) | 2011-07-08 | 2015-12-22 | Defensin Therapeutics Aps | Oral treatment of inflammatory bowel disease |
| EP2750697A4 (en) | 2011-09-02 | 2015-03-25 | Medtronic Inc | CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
| EP2804623B1 (en) | 2012-01-12 | 2019-08-07 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
| LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| BR112014023200A2 (pt) | 2012-03-20 | 2018-09-18 | Albert Einstein College Of Medicine Of Yeshiva University | uso de uma composição |
| WO2013170636A1 (zh) * | 2012-05-18 | 2013-11-21 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | Chimeric clotting factors |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| CN110054699A (zh) | 2012-07-11 | 2019-07-26 | 比奥贝拉蒂治疗公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| US9827250B2 (en) * | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| US10391152B2 (en) | 2012-10-18 | 2019-08-27 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| US10772940B1 (en) | 2012-12-11 | 2020-09-15 | University Of Kentucky Research Foundation | Cocaine hydrolase-FC fusion proteins for cocaine and methods for utilizing the same |
| AR094481A1 (es) * | 2013-01-15 | 2015-08-05 | Teva Pharma | Formulaciones de albu-bche (albúmina-butirilcolinesterasa), preparación y sus usos |
| FI3889173T3 (fi) | 2013-02-15 | 2023-10-02 | Bioverativ Therapeutics Inc | Optimoitu tekijä viii:n geeni |
| WO2014125082A1 (en) | 2013-02-16 | 2014-08-21 | Novozymes Biopharma Dk A/S | Pharmacokinetic animal model |
| EP2968587A2 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| TWI828269B (zh) | 2013-03-15 | 2024-01-01 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
| MX2015016567A (es) | 2013-06-28 | 2016-03-31 | Biogen Ma Inc | Enlazador escindible por trombina con xten y usos del mismo. |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| US20160311885A1 (en) | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
| EP3048899B1 (en) | 2013-09-25 | 2021-09-08 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| WO2015070014A1 (en) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Procoagulant fusion compound |
| SG11201605242YA (en) | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
| WO2015168284A1 (en) * | 2014-04-30 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Albumin-bche in detoxification of neurotoxins |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| AP2017009826A0 (en) | 2014-09-26 | 2017-03-31 | Bayer Pharma AG | Stabilized adrenomedullin derivatives and use thereof |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| WO2016090251A1 (en) | 2014-12-05 | 2016-06-09 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| IL257231B (en) | 2015-08-03 | 2022-09-01 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| AU2016308624B2 (en) | 2015-08-17 | 2022-06-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
| WO2017037812A1 (ja) * | 2015-08-29 | 2017-03-09 | 株式会社メドレックス | 酸捕捉剤を含有する貼付製剤 |
| EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| KR20180125979A (ko) | 2016-04-01 | 2018-11-26 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타아제로 근육 약화의 치료 |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 気管気管支軟化症の治療方法 |
| JP2020500306A (ja) | 2016-11-04 | 2020-01-09 | オーフス ウニベルシテット | 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療 |
| JP2019536794A (ja) | 2016-12-02 | 2019-12-19 | バイオベラティブ セラピューティクス インコーポレイテッド | 凝固因子に対する免疫寛容を誘導する方法 |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
| WO2018144623A1 (en) | 2017-01-31 | 2018-08-09 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| MX2019011508A (es) | 2017-03-31 | 2019-11-01 | Alexion Pharma Inc | Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes. |
| US20200171128A1 (en) * | 2017-05-19 | 2020-06-04 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for improving cognition |
| BR112020002394A2 (pt) | 2017-08-09 | 2020-07-28 | Bioverativ Therapeutics Inc. | moléculas de ácidos nucleicos e usos das mesmas |
| AU2019215063B2 (en) | 2018-02-01 | 2025-10-16 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
| KR102824112B1 (ko) | 2018-03-28 | 2025-06-24 | 브리스톨-마이어스 스큅 컴퍼니 | 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| SI3793588T1 (sl) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Postopki zdravljenja hemofilije A |
| AU2019297327A1 (en) | 2018-07-03 | 2021-02-18 | Bristol-Myers Squibb Company | FGF21 formulations |
| KR102925832B1 (ko) | 2018-08-09 | 2026-02-11 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도 |
| JP7820148B2 (ja) | 2018-08-10 | 2026-02-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法 |
| BR112021010047A2 (pt) | 2018-12-06 | 2021-08-24 | Bioverativ Therapeutics Inc. | Uso de vetores lentivirais expressando o fator ix |
| JP2022536474A (ja) * | 2019-06-10 | 2022-08-17 | アクセス ツー アドバンスト ヘルス インスティチュート | アストロウイルスレプリコンの方法および組成物 |
| EP3986918A1 (en) | 2019-06-18 | 2022-04-27 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| JP7523541B2 (ja) * | 2019-11-27 | 2024-07-26 | ワンジーン バイオテクノロジー インコーポレイテッド | 生体内における持続時間が延長された多機能性多重特異性マルチマー生体分子重合体 |
| MX2022007114A (es) | 2019-12-09 | 2022-07-11 | Alexion Pharma Inc | Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos. |
| KR20230074703A (ko) | 2020-06-24 | 2023-05-31 | 바이오버라티브 테라퓨틱스 인크. | 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법 |
| MX2023002673A (es) | 2020-09-04 | 2023-05-12 | Alexion Pharma Inc | Métodos para el tratamiento de trastornos de mineralización ósea. |
| CN112725305B (zh) * | 2021-01-13 | 2022-11-04 | 云南师范大学 | 热盐性敏感的菊粉酶突变体MutY119D及其制备方法 |
| EP4291224A4 (en) | 2021-02-12 | 2025-01-01 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| CN119823285B (zh) * | 2025-01-09 | 2025-08-19 | 石家庄市农林科学研究院 | 一种貉α干扰素和β防御素融合蛋白及其编码基因和应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US5514567A (en) * | 1979-01-30 | 1996-05-07 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| US5326859A (en) * | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
| US4530901A (en) * | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4456748A (en) * | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
| IT1167610B (it) * | 1982-01-19 | 1987-05-13 | Cetus Corp | Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione |
| US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| JPS60136596A (ja) * | 1983-12-26 | 1985-07-20 | Suntory Ltd | ペプチド及びこれを有効成分とする利尿剤 |
| US4716217A (en) * | 1984-08-31 | 1987-12-29 | University Patents, Inc. | Hybrid lymphoblastoid-leukocyte human interferons |
| US4734491A (en) * | 1984-08-31 | 1988-03-29 | University Patents, Inc. | DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8510219D0 (en) | 1985-04-22 | 1985-05-30 | Bass Plc | Isolation of fermentation products |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| JPS6296086A (ja) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | 複合プラスミド |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5002764A (en) * | 1986-08-12 | 1991-03-26 | Schering Corporation | Treatment of actinic keratoses with alpha2 interferon |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| CN1033030C (zh) | 1988-06-24 | 1996-10-16 | 唐化学原料公司 | 大环双官能螯合剂及其配合物和抗体共轭物的制备方法 |
| JP2831073B2 (ja) | 1988-06-24 | 1998-12-02 | ザ ダウ ケミカル カンパニー | 大環状二官能キレート剤、その錯体及びそれらの抗体接合体 |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| AU633020B2 (en) | 1988-07-23 | 1993-01-21 | Novozymes Delta Limited | New secretory leader sequences |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
| GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
| US5173408A (en) | 1989-11-13 | 1992-12-22 | Lange Louis George Iii | Mammalian pancreatic cholesterol esterase |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH07108232B2 (ja) | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
| WO1992009691A1 (fr) * | 1990-11-29 | 1992-06-11 | Institut National De La Recherche Agronomique - I.N.R.A. | Nouveaux variants derives des interferons de type i, leur procede de production, et leurs applications |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5540923A (en) * | 1991-12-06 | 1996-07-30 | Landsforeningen Til Kraeftens Bekaemplse | Interferon proteins |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| MD1699F2 (ro) | 1992-07-31 | 2001-07-31 | Genentech, Inc. | Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5932780A (en) | 1994-02-28 | 1999-08-03 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Transgenic non-human animal assay system for anti-cholinesterase substances |
| GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| US5695750A (en) * | 1994-11-25 | 1997-12-09 | The United States Of America As Represented By The Secretary Of The Army | Compositions for use to deactivate organophosphates |
| US5480640A (en) * | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
| US6001625A (en) * | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| CA2248538A1 (en) * | 1996-03-14 | 1997-09-18 | The Immune Response Corporation | Targeted delivery of genes encoding interferon |
| AU7364696A (en) | 1996-09-18 | 1998-04-14 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
| EP1274720A4 (en) * | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| US7070973B2 (en) * | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
| AU2002248256B2 (en) * | 2000-12-26 | 2006-09-28 | Applied Molecular Evolution, Inc. | Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use |
| US7049121B2 (en) * | 2001-12-20 | 2006-05-23 | Applied Molecular Evolution | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US6989261B2 (en) * | 2001-12-20 | 2006-01-24 | Eli Lilly And Company | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use |
| US20060253913A1 (en) * | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
| PT1463751E (pt) * | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| EP1463752A4 (en) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| WO2003054182A2 (en) * | 2001-12-21 | 2003-07-03 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
| CA2513213C (en) * | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP5010923B2 (ja) | 2004-02-09 | 2012-08-29 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合蛋白質 |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
| JP2009504157A (ja) | 2005-08-12 | 2009-02-05 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合タンパク質 |
| US8008257B2 (en) * | 2005-10-20 | 2011-08-30 | University Of Ottawa Heart Institute | ANF fusion proteins |
| AU2007258609B2 (en) * | 2006-06-07 | 2013-01-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
-
2007
- 2007-10-31 US US11/932,823 patent/US20080194481A1/en not_active Abandoned
-
2008
- 2008-10-30 CA CA2703943A patent/CA2703943A1/en not_active Abandoned
- 2008-10-30 WO PCT/US2008/012306 patent/WO2009058322A1/en not_active Ceased
- 2008-10-30 EP EP08843705A patent/EP2211888A4/en not_active Withdrawn
- 2008-10-30 JP JP2010532056A patent/JP2011501959A/ja active Pending
- 2008-10-30 AU AU2008319332A patent/AU2008319332B2/en active Active
-
2010
- 2010-04-06 IL IL204839A patent/IL204839A0/en unknown
- 2010-06-03 US US12/793,658 patent/US8287859B2/en not_active Expired - Lifetime
-
2013
- 2013-11-11 JP JP2013233069A patent/JP5856131B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200181216A1 (en) | Hsa-gdf-15 fusion polypeptide and use thereof | |
| CN101389648B (zh) | 肽胃泌酸调节素衍生物 | |
| TWI760333B (zh) | Ｇｄｆ１５融合蛋白及其用途 | |
| CN101367873B (zh) | 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用 | |
| CN103547590B (zh) | 高度可溶性瘦蛋白 | |
| CN102197049B (zh) | 胰岛淀粉样多肽衍生物 | |
| JP2009525052A5 (enExample) | ||
| US20080095758A1 (en) | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | |
| JP2012529297A5 (enExample) | ||
| CN108473546B (zh) | Mg53突变体及其制备方法和用途 | |
| JP2007521807A5 (enExample) | ||
| CN102153652A (zh) | 一种融合蛋白的表达方法及用途 | |
| JP2013545724A (ja) | 作用持続時間が増した改変ポリペプチド | |
| WO2011028344A2 (en) | Interleukin-1 receptor antagonist compositions and methods of making and using same | |
| CN106432509B (zh) | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 | |
| CN101240033B (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
| JP2012511506A (ja) | 新規インスリンアナログ | |
| US8008257B2 (en) | ANF fusion proteins | |
| JP6612360B2 (ja) | 薬用作用を有する融合タンパク質複合体および融合タンパク質 | |
| JP2013520166A5 (enExample) | ||
| KR20190121305A (ko) | apoC-II 모방 펩타이드 | |
| WO2015000413A1 (zh) | 长效降血糖融合蛋白 | |
| CN1320117C (zh) | 脂联素－胰升糖素样肽－1类似肽融合蛋白表达载体及构建 | |
| JP2024517967A (ja) | 修飾ｂ型ナトリウム利尿ペプチド | |
| CN103159847A (zh) | 一种利钠肽及其基因与用途 |